Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.81 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 10/20 | 0.65 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211435 | 0.90 | PIM1 (1.00) | PIM1PIM2HPGDTDP1AKR1B1 | |
| SCHEMBL211434 | 0.90 | PIM1 (1.00) | PIM1PIM2HPGDTDP1AKR1B1 | |
| SCHEMBL5672818 | 0.90 | PIM1 (1.00) | PIM1PIM2HPGDTDP1AKR1B1 | |
| SCHEMBL212733 | 0.86 | GPR35 (0.70) | PIM1PIM2HPGDCISD1TDP1 | |
| SCHEMBL212735 | 0.86 | GPR35 (0.70) | PIM1PIM2HPGDCISD1TDP1 | |
| SCHEMBL212734 | 0.86 | GPR35 (0.70) | PIM1PIM2HPGDCISD1TDP1 | |
| SCHEMBL2759606 | 0.82 | PIM1 (0.54) | PIM1PIM2HPGDCISD1TDP1 | |
| SCHEMBL7078703 | 0.81 | GPR35 (0.74) | PIM1PIM2HPGDCISD1GPR35 | |
| SCHEMBL7078705 | 0.81 | GPR35 (0.74) | PIM1PIM2HPGDCISD1GPR35 | |
| SCHEMBL9326976 | 0.80 | HPGD (0.80) | PIM1PIM2HPGDCISD1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | PIM1 2009/4885PIM2 2680/4885HPGD 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.